Browse News
Filter News
Found 730 articles
-
Pharmaceutical CDMO Industry is Rising Rapidly Up to USD 295.95 Bn by 2033
4/19/2024
The global pharmaceutical CDMO market size was accounted for USD 146.29 billion in 2023 and it is increasing around USD 295.95 billion by 2033 with a CAGR of 7.3% from 2024 to 2033. according to a new report by Nova One Advisor.
-
Plus, how the geopolitical tensions with China will affect U.S. biopharma
-
Clinical Trials Market Size to Increase USD 153.59 Billion by 2033
4/9/2024
According to Nova One Advisor, the global clinical trials market size was estimated at USD 81.90 billion in 2023 and it is projected to increase USD 153.59 billion by 2033 with a CAGR of 6.49% from 2024 to 2033.
-
D3 Bio Completes Series A+ Round to Advance Innovative Oncology Pipeline
4/8/2024
D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its closing of Series A+ financing round led by Medicxi, a leading European life sciences investment firm.
-
Recent warnings about Chinese biopharma partners from members of Congress and U.S. intelligence officials have reached a fever pitch in Washington.
-
Three Biopharma firms disclosed concerns about how emerging geopolitical tensions between the U.S. and China might impact their business with the contract manufacturer.
-
Plus, another big buy points to strength of CDMO market and a new treatment for pulmonary arterial hypertension
-
Alongside the abrupt departure of Chinese biotech WuXi from BIO, Congress is rattling sabers over perceived national security implications of the U.S.’s R&D relationship with the country.
-
U.S. intelligence officials have informed senators that China-based biotech WuXi AppTec transferred an American client’s intellectual property to the Chinese government without consent, reports Reuters.
-
Cell And Gene Therapy CDMO Market Size to Reach USD 69.11 Bn by 2033
3/28/2024
The global cell and gene therapy CDMO Market size was valued at USD 5.90 billion in 2023 and is projected to reach USD 69.11 billion by 2033,
-
Advanced Therapy Medicinal Products CDMO Industry is Rising Rapidly
3/28/2024
According to latest study, the global advanced therapy medicinal products CDMO Market size was valued at USD 6.10 billion in 2023 and is projected to reach USD 34.53 billion by 2033
-
The FDA took center stage last week as it approved the first-ever MASH therapy and considered additional approvals for CAR-T therapies, whose safety the agency has been investigating since last year.
-
In a change of position as congressional scrutiny of WuXi AppTec grows, the Biotechnology Innovation Organization announced it is taking steps to separate from the China-based biotech.
-
Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
2/27/2024
Alzheon, Inc. announced its participation in the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Lisbon, Portugal from March 5–9, 2024.
-
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma
2/20/2024
WuXi Advanced Therapies today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024.
-
Sirona Biochem Corporate Update January 2024
1/24/2024
We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem's path forward.
-
CORRECTION -- Sirona Biochem Corporate Update January 2024
1/24/2024
We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem's path forward.
-
NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings
1/8/2024
NightHawk Biosciences today announced that it is changing the name of the Company to Scorpius Holdings, Inc. (“Scorpius”) to better reflect the Company’s successful shift into a pure-play, large molecule biomanufacturing CDMO.
-
Preclinical CRO Market Poised to Surge USD 10.60 Bn by 2032
12/13/2023
The global preclinical CRO market size was exhibited at USD 5.33 billion in 2022 and is projected to hit around USD 10.60 billion by 2032, growing at a CAGR of 7.11% during the forecast period 2023 to 2032.
-
Drug Discovery Services Market Size To Hold USD 75.68 Bn By 2032
11/29/2023
The global drug discovery services market size was exhibited at USD 19.37 billion in 2022 and it is expected to hit around USD 75.68 billion by 2032, growing at a CAGR of 14.6% during the forecast period from 2023 to 2032.